FDA panel loosens restrictions for controversial peptides popular online
Summary
A US FDA advisory panel voted to ease rules on certain peptides like BPC-157, TB-500, and KPV, allowing specialized pharmacies to produce them for prescription use. These peptides are popular online but lack thorough human safety studies, and health experts warn about unknown risks.Key Facts
- The FDA panel narrowly approved loosening restrictions on some peptides, which are small proteins the body naturally makes.
- Peptides like BPC-157 and KPV are popular in online wellness communities for claims about healing, muscle building, and skin improvement, though these claims are unproven.
- Specialized pharmacies, called compound pharmacies, would be allowed to make these peptides if rules change.
- The FDA does not have to follow the advisory panel but often does.
- Health Secretary Robert F. Kennedy supports easing these peptide restrictions, reversing previous limits set during the Biden administration.
- Peptides like BPC-157 have been studied in animals but lack extensive human trials, leading to safety concerns from experts.
- These peptides are banned in sports by the World Anti-Doping Agency due to unknown safety and effects.
- Some panel members voted against approving peptides citing lack of data, while others supported medical freedom and broader access.
Read the Full Article
This is a fact-based summary from The Actual News. Click below to read the complete story directly from the original source.
